The frequency of HER2 amplification and the percentage of membrane staining in HER2 2+invasive carcinomas of the breast Reply

被引：0
|
作者：
Polonia, Antonio [1 ,2 ]
Canelas, Carolina [1 ,2 ]
Caramelo, Ana [1 ,2 ]
机构：
[1] Univ Porto, Inst Mol Pathol & Immunol, Dept Pathol, Ipatimup Diagnost, Rua Julio Amaral Carvalho 45, P-4200135 Porto, Portugal
[2] Univ Porto, I3S Inst Invest & Inovacao Saude, Porto, Portugal
来源：
VIRCHOWS ARCHIV | 2022年 / 481卷 / 02期
关键词：
D O I：
10.1007/s00428-022-03357-w
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：329 / 330
页数：2
相关论文
共 50 条
  • [1] The frequency of HER2 amplification and the percentage of membrane staining in HER2 2+invasive carcinomas of the breast
    Lee, Andrew H. S.
    Ellis, Ian O.
    VIRCHOWS ARCHIV, 2022, 481 (02) : 327 - 327
  • [2] The frequency of HER2 amplification and the percentage of membrane staining in HER2 2 + invasive carcinomas of the breast
    Andrew H. S. Lee
    Ian O. Ellis
    Virchows Archiv, 2022, 481 : 327 - 327
  • [3] Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification
    Lee, Andrew H. S.
    Key, Heather P.
    Bell, Jane A.
    Hodi, Zsolt
    Ellis, Ian O.
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (06) : 490 - 492
  • [4] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [5] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    LABORATORY INVESTIGATION, 2019, 99
  • [6] Phosphorylated HER2 expression is highly specific for HER2 gene amplification in female invasive ductal carcinomas
    Koseki, Masato
    Taniyama, Kiyomi
    Motoshita, Junichi
    Teramoto, Seiichi
    Tani, Yoichi
    CANCER RESEARCH, 2006, 66 (08)
  • [7] Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+Invasive Breast Cancer
    Yamada, Mai
    Kubo, Makoto
    Yamamoto, Hidetaka
    Yamashita, Nami
    Kai, Masaya
    Zaguirre, Karen
    Kaneshiro, Kazuhisa
    Shimazaki, Akiko
    Hayashi, Saori
    Kawaji, Hitomi
    Mori, Masaki
    Oda, Yoshinao
    Nakamura, Masafumi
    ANTICANCER RESEARCH, 2021, 41 (08) : 4143 - 4149
  • [8] Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab
    Franco, Andreia Fabiana do Vale
    Malinverni, Andrea Cristina Moraes
    Waitzberg, Angela Flavia Logullo
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 252
  • [9] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Lauterlein, Jens-Jacob L.
    Petersen, Eva R. B.
    Olsen, Dorte Aa
    Ostergaard, Birthe
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
  • [10] HER2 staining intensity has prognostic impact on patients with HER2 type invasive breast cancer
    Yi-Hsuan, H.
    Yen-Shu, L.
    Chih-Yi, H.
    Ling-Ming, T.
    ANNALS OF ONCOLOGY, 2018, 29
12345